SCHEMBL6897905

SCHEMBL6897905

COC(=O)c1cccc2c1c1c(O)cc(-c3ccc(Cl)cc3)cc1n2Cc1ccccc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.43
TBXA2R P21731 1/20 0.43
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
MAPT P10636 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
SCN2A Q99250 1/20 0.40
SCN10A Q9Y5Y9 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
HSP90AA1 P07900 1/20 0.39
HSP90B1 P14625 1/20 0.39
PLA2G2A P14555 1/20 0.38
LMNA P02545 3/20 0.38
HTT P42858 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6891733 0.92 MAPT (0.43) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL6887896 0.91 MAPT (0.44) DRD2TBXA2RSLC6A4SLC6A3MAPT
SCHEMBL6895138 0.90 HSP90AA1 (0.43) DRD2TBXA2RSLC6A4SLC6A3MAPT
SCHEMBL6889740 0.90 SLC6A4 (0.41) DRD2TBXA2RSLC6A4SLC6A3MAPT
SCHEMBL6896346 0.90 SLC6A3 (0.41) DRD2TBXA2RSLC6A4SLC6A3MAPT
SCHEMBL6770301 0.89 PLA2G2A (0.41) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL6690879 0.89 DRD2 (0.47) DRD2TBXA2RSLC6A4SLC6A3MAPT
SCHEMBL6889876 0.89 MAPK8 (0.44) DRD2TBXA2RSLC6A4SLC6A3MAPT
SCHEMBL6894724 0.89 SLC6A3 (0.48) DRD2TBXA2RSLC6A4SLC6A3MAPT
SCHEMBL6895819 0.87 GRIN1 (0.50) DRD2TBXA2RSLC6A4SLC6A3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235926-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC. 2004-11-25 US disclosed
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235926-A1 Cannabinoid receptor ligands and uses thereof CNR1, CNR2, GPR18 DRD2 649/4885TBXA2R 67/4885SLC6A4 1413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.